In brief
Oncoclínicas elected Maurício Hasson as CFO and IR officer, replacing interim Isaac Quintino, who leaves the company.
It is the second change in the post in under a year, during the R$ 5.1 billion out-of-court restructuring.
What we know
04Verified fact · material
The Oncoclínicas board elected on September 14 Maurício Hasson as chief financial and investor relations officer, and Isaac Quintino leaves the posts after the transition, per Reuters via InfoMoney, Money Times and Bloomberg Línea.
The fact that defines the event.
Verified fact · material
Quintino had held the roles on an interim basis since April 24, after eight years at the group, and Hasson has more than 14 years in CFO roles, with a stint at Oncoclínicas between 2015 and 2016 and at investment banks in Brazil and the United States, per InfoMoney and Bloomberg Línea.
Profile and timeline.
Verified fact
It is the second CFO change in under a year and comes amid the out-of-court restructuring of R$ 5.1 billion in debt, with JPMorgan pointing to the search for a profile to lead the process, per Bloomberg Línea; the company statement does not mention the restructuring, per InfoMoney.
Restructuring context, one source.
Context
Oncoclínicas has been negotiating its debt restructuring with creditors since the first half and already changed its CFO in April, when Quintino took over as interim.
Recent history.
Sources[03]
Transmission to assets
Market read-through
For bonds and ONCO3OncoclínicasOrganizationLatin America's largest private oncology network, listed on B3 as ONCO3. Subject of a mandatory tender offer CVM imposed on US manager Centaurus in August 2026, under the bylaws' 15% poison pill.Open in the Market Map ↗, a CFO with an investment banking background signals focus on creditor talks, but turnover in the post raises execution risk.
The R$ 5.1 billion restructuring remains the dominant factor for the stock.
Portfolio impact
01Changing the lead negotiator mid-restructuring changes the pace and tone with creditors.
Uncertain until the final restructuring design.
What would change the view: Depends on the terms Hasson presents to creditors.
Direction is an explanatory hypothesis, not a forecast or recommendation.
Next signals
What to watch
- Terms of the out-of-court restructuring and creditor take-up.
- 3Q26 results and cash.
- Bond reaction to the appointment.
Limits of the reporting
What remains uncertain
- The R$ 5.1 billion figure and the second-change characterisation come only from Bloomberg Línea.
- InfoMoney and Money Times reproduce Reuters.